hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.2478/acph-2014-0015

Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme

USMAN SUMO FRIEND TAMBUNAN ; Department of Chemistry, Faculty of Mathematics and Sciences, Depok, University of Indonesia
ARLI ADITYA PARIKESIT ; Department of Chemistry, Faculty of Mathematics and Sciences, Depok, University of Indonesia
FEIMMY RUTH PRATIWI SIPAHUTAR ; Department of Chemistry, Faculty of Mathematics and Sciences, Depok, University of Indonesia

Puni tekst: engleski, pdf (290 KB) str. 157-172 preuzimanja: 707* citiraj
APA 6th Edition
TAMBUNAN, U.S.F., PARIKESIT, A.A. i SIPAHUTAR, F.R.P. (2014). Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme. Acta Pharmaceutica, 64 (2), 157-172. https://doi.org/10.2478/acph-2014-0015
MLA 8th Edition
TAMBUNAN, USMAN SUMO FRIEND, et al. "Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme." Acta Pharmaceutica, vol. 64, br. 2, 2014, str. 157-172. https://doi.org/10.2478/acph-2014-0015. Citirano 22.09.2021.
Chicago 17th Edition
TAMBUNAN, USMAN SUMO FRIEND, ARLI ADITYA PARIKESIT i FEIMMY RUTH PRATIWI SIPAHUTAR. "Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme." Acta Pharmaceutica 64, br. 2 (2014): 157-172. https://doi.org/10.2478/acph-2014-0015
Harvard
TAMBUNAN, U.S.F., PARIKESIT, A.A., i SIPAHUTAR, F.R.P. (2014). 'Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme', Acta Pharmaceutica, 64(2), str. 157-172. https://doi.org/10.2478/acph-2014-0015
Vancouver
TAMBUNAN USF, PARIKESIT AA, SIPAHUTAR FRP. Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme. Acta Pharm. [Internet]. 2014 [pristupljeno 22.09.2021.];64(2):157-172. https://doi.org/10.2478/acph-2014-0015
IEEE
U.S.F. TAMBUNAN, A.A. PARIKESIT i F.R.P. SIPAHUTAR, "Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme", Acta Pharmaceutica, vol.64, br. 2, str. 157-172, 2014. [Online]. https://doi.org/10.2478/acph-2014-0015

Sažetak
It is critical to seek potential alternative treatments for H1N1 infections by inhibiting neuraminidase-1 enzyme. One of the viable options for inhibiting the activity of neuraminidase-1 is peptide drug design. In order to increase peptide stability, cyclization is necessary to prevent its digestion by protease enzyme. Cyclization of peptide ligands by formation of disulfide bridges is preferable for designing inhibitors of neuraminidase-1 because of their high activity and specificity. Here we designed ligands by using molecular docking, drug scan and dynamics computational methods. Based on our docking results, short polypeptides of cystein-arginine-methionine-tyrosine-proline-cysteine (CRMYPC) and cysteine-arginine-aspargine-phenylalanine-proline-cysteine (CRNFPC) have good residual interactions with the target and the binding energy ΔGbinding of –31.7402 and –31.0144 kcal mol–1, respectively. These values are much lower than those of the standards, and it means that both ligands are more accessible to ligand-receptor binding. Based on drug scan results, both of these ligands are neither mutagenic nor carcinogenic. They also show good oral bioavailability. Moreover, both ligands show relatively stable molecular dynamics progression of RMSD versus time plot. However, based on our metods, the CRMYPC ligand has sufficient hydrogen bonding interactions with residues of the active side of neuraminidase-1 and can be therefore proposed as a potential inhibitor of neuraminidase-1.

Ključne riječi
H1N1; neuraminidase-1; cyclic peptide disulfide; molecular docking; molecular dynamics

Hrčak ID: 114599

URI
https://hrcak.srce.hr/114599

Posjeta: 1.113 *